Answers are grounded in this paper and cite their sources.
Basket trial reveals molecularly matched therapy improves progression-free survival in refractory cancer, indicating the clinical value of personalized treatment selection.
PURPOSE: SHIVA02 is a tissue-agnostic precision medicine basket trial assessing a molecularly targeted strategy in refractory cancer patients using patients as their own-controls to assess the efficacy of the strategy. PATIENTS AND METHODS: Patients with cancers refractory to standard-of-care underwent molecular profiling and received standard therapy followed, if possible, by matched therapy guided by a Molecular Biology Board. Tumor evaluations were performed every 2 months according to RECIST1.1 on both treatments in order to reliably assess the PFS ratio. RESULTS: Among 263 patients enrolled, molecular profiling was successful in 192 patients (73%), and 34 patients (13%) received matched therapy and were eligible for PFS ratio analyses. The median PFS1 was 2.1 months (95% CI [confidence interval] 1.8 to 3.6) and the median PFS2 was 2.0 months (95% CI 1.8 to 2.7). A PFS ratio exceeding 1.3 or 1.5 was observed in 11 (32%) and 8 (24%) patients, respectively. Overall survival was prolonged in the subgroup of patients evaluable for PFS ratio. Prognostic factors such as ECOG performance status and RMH score significantly influenced overall survival, highlighting the importance of patient selection in precision oncology trials. CONCLUSIONS: Using a prospective and standardized approach for evaluating PFS on both standard and matched therapies, 32% of patients receiving matched therapy benefited from the approach with a PFS ratio > 1.3.
No takes yet. Share an insight, caveat, or question.
Rusquec et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: